Your browser version is outdated. We recommend that you update your browser to the latest version.












Our lead candidate is a liposome formulation of a TLR7 agonist that is a potent stimulator of the innate immune system. 

We have currently demonstrated proof of principle with our technology in preclinical models. The studies demonstrate a potent anti-metastatic activity in experimental mouse models.

Cancer immunotherapy nanoparticle

Our formulation is a ”simple” formulation in the sense that we do not depend on targeting molecules on the liposome surface. Instead the liposomes target to monocytes and dendritic cells due to modification of the liposome surface. The "simplicity" of our technology is expected to lead to reduced risks and lower cost during development.

Boosting an immune memory effect

We have demonstrated a strong effect of our technology in combination with fractionated radiotherapy and the clinically used Doxil formulation, with complete tumor remission in a number of mice. Most importantly, these mice showed ability to eliminate new tumors upon rechallenge, demonstrating that our TLR7-delivery technology have educated the immune system to recognize and eliminate tumor cells, mimicing the situation in metastatic patients. This memory effect is believed to be able to approach and eliminate not only the primary tumor, but also metastasis originating from the primary tumor at distant sites.

Clinical development

We expect to initiate a clinical phase I study in patients with metastatic cancer, and extent into a phase IIA in combination with existing therapies.

Clinical potential

There is a strong clinical and scientific evidence for improved outcome for patients in combination with existing cancer treatments:

  • Fractionated Radiotherapy

  • Monoclonal antibody therapy (e.g. Rituximab and Trastuzumab)

  • Chemotherapy (e.g. Antracyclins, oxaliplatin, cyclophosphamide)

  • Immune checkpoint inhibitors